Pulmatrix, Inc. (PULM) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US74584P3010
Pulmatrix, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -5.17 m USD |
| EBIT | -5.31 m USD |
| Net income | -5.16 m USD |
| Diluted EPS – continuing operations | -1.41 USD |
Full history since 2011, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Pulmatrix, Inc.
Pulmatrix, Inc., a biopharmaceutical company, focused on development of novel inhaled therapeutic products to prevent and treat migraine and respiratory diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor compounds. The company was founded in 2003 and is headquartered in Framingham, Massachusetts.
More stocks
- SPECIFICITY, INC. (SPTY)
- Perfect Moment Ltd. (PMNT)
- GD Culture Group Ltd (GDC)
- I-ON Digital Corp. (IONI)
- Scienture Holdings, Inc. (SCNX)
- AMARIN CORP PLC\UK (AMRN)
- Cadrenal Therapeutics, Inc. (CVKD)
- Aqua Metals, Inc. (AQMS)
- REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH)
- AleeanPeace Group Holdings Ltd (APGH)
- Luvu Brands, Inc. (LUVU)
- Versus Systems Inc. (VS)
Not investment advice. All data without warranty, price as of 12.11.2026. Details in the risk notice.